Market Overview

CardioNet Says Study Supports Efficacy of MCOTTM for Detection of Atrial Fibrillation in Stroke Patients

Related BEAT
Covance Posts In-line Q1 Earnings; Falls on Trimmed View - Analyst Blog
How BioTelemetry (BEAT) Stock Stands Out in a Strong Industry - Tale of the Tape

CardioNet, Inc. (NASDAQ: BEAT), the leading wireless medical technology company with an initial focus on the diagnosis and monitoring of cardiac arrhythmias, today announced the publication of a new clinical study that further supports CardioNet's Mobile Cardiac Outpatient Telemetry (MCOT^TM) in detecting a high rate of atrial fibrillation in cryptogenic stroke.

This new study, titled “Outpatient cardiac telemetry detects a high rate of atrial fibrillation in cryptogenic stroke,” was authored by Daniel J Miller, MD, et al, Henry Ford Hospital, Department of Neurology, and was published online on October 24th in the Journal of the Neurological Sciences. The study showed that MCOT^TM frequently detects paroxysmal atrial fibrillation in patients with cryptogenic stroke and transient ischemic attack (TIA). This study is confirmation of the value of MCOT^TM for monitoring patients with cryptogenic stroke and TIA for atrial fibrillation, one potential and treatable, cause of stroke.

Posted-In: News FDA

 

Most Popular

Related Articles (BEAT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters